Recombinant Human SLAMF3/CD229 Protein (His Tag)

Catalog Number: PKSH033121



Description			
Species	Human		
Mol_Mass	45.6 kDa		
Accession	Q9HBG7		
Bio-activity	Not validated for activity		
Properties			
Purity	> 95 % as determined by reducing SDS-PAGE.		
Endotoxin	< 1.0 EU per µg of the protein as determined by the LAL method.		
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80		
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of		
	reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.		
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.		
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.		
	Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants		
	before lyophilization.		
	Please refer to the specific buffer information in the printed manual.		
Reconstitution	Please refer to the printed manual for detailed information.		
Data			

Note: Centrifuge before opening to ensure complete recovery of vial contents.

kDa	MK	R
120 90 60	=	ce"
40	Elat	
30	-	Inscience
20	-	. Jan
14 <sup>bsch</sup>		

> 95 % as determined by reducing SDS-PAGE.

## Background

SLAMF3 (CD229) is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Mature human SLAMF3 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig-like V-set and two Ig-like truncated C2-set domains. The ECD of human SLAMF3 shares 57% - 59% aa sequence identity with mouse and rat SLAMF3. Within the first two Ig-like domains that are common to all SLAM proteins, human SLAMF3 shares 24% - 39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. It is expressed on T and B cells, thymocytes, and more weakly on NK cells. It may participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. SLAMF3 may be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. It also disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells and negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells.

## For Research Use Only